| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Centella asiatica / Gotu kola → AsiaticosideCentella asiatica, commonly known as Gotu kola, is a medicinal botanical used mainly for wound healing, skin repair, microcirculation support, anti-inflammatory effects, and possible neuroprotective activity.
Asiaticoside is one of the major active and marker compounds in Centella asiatica.
Structure: Centella asiatica / Gotu kola → Asiaticoside → Madecassoside → Asiatic acid → Madecassic acid Centella asiatica / Gotu kola → asiaticoside — Centella asiatica is a medicinal botanical extract source, and asiaticoside is one of its major pentacyclic triterpenoid saponin marker constituents. The formal classification is botanical standardized extract / natural-product triterpenoid saponin modality, not an approved anticancer drug. The principal active family includes asiaticoside, madecassoside, asiatic acid, and madecassic acid; asiaticoside can also be metabolically linked to asiatic acid. Asiaticoside as the main active marker, with Centella asiatica standardized extract as the primary product. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral translation is constrained by variable extract composition, limited dissolution and bioavailability of triterpenes, metabolism of glycosides to aglycones, and formulation dependence. Standardized extracts such as ECa 233 and aqueous Centella asiatica products have human phase-1 PK data, but systemic exposure is still not equivalent to common high-concentration in-vitro cancer experiments. In-vitro vs systemic exposure relevance: Cancer-cell studies commonly use micromolar asiaticoside or asiatic-acid exposures that may exceed or not cleanly map onto achievable plasma exposure after oral botanical dosing. Topical and local tissue uses are more plausible for skin/wound biology than systemic anticancer effects. For cancer translation, the entry should be treated as concentration- and formulation-dependent. Clinical evidence status: Cancer relevance is weak / preclinical only, with no established oncology indication. Human evidence is stronger for wound healing, venous/skin-related uses, and early cognitive/AD-oriented safety or PK studies than for cancer treatment. AD relevance is possible / early clinical, with phase-1 target-engagement work in mild cognitive impairment or mild Alzheimer’s disease, but no proven disease-modifying efficacy. Centella asiatica and Asiaticoside Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr AD relevance: Possible / preclinical. Interest is mainly through neuroinflammation, oxidative stress, mitochondrial protection, and general neuroprotective mechanisms. Alzheimer’s disease relevance: Centella asiatica / Gotu kola has a plausible but unproven AD-oriented profile. The strongest rationale is not direct amyloid clearance as an established clinical effect, but combined modulation of neuroinflammation, oxidative stress, mitochondrial metabolism, synaptic or neuronal viability markers, and vascular/microcirculatory support. Human evidence is early: phase-1 PK/safety and target-engagement studies exist in older adults with mild cognitive impairment or mild Alzheimer’s disease, but efficacy remains unproven. Clinical evidence status: AD / cognition evidence is preclinical plus small human and phase-1 clinical work. Early translational / investigational rather than established therapy. Cancer relevance: Weak / preclinical. AD-Oriented Mechanistic Profile
|
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 6656- | Cen, | Recent insights into therapeutic potential and nanostructured carrier systems of Centella asiatica: An evidence-based review |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 6652- | Cen, | AA-PMe, a novel asiatic acid derivative, induces apoptosis and suppresses proliferation, migration, and invasion of gastric cancer cells |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | HGC27 |
| 6651- | Cen, | Study of the cytotoxicity of asiaticoside on rats and tumour cells |
| - | vitro+vivo, | BC, | MCF-7 |
| 6615- | Cen, | Asiaticoside suppresses cell proliferation by inhibiting the NF-κB signaling pathway in colorectal cancer |
| - | vitro+vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | LoVo |
| 6645- | Cen, | Can Asiatic Acid from Centella asiatica Be a Potential Remedy in Cancer Therapy?—A Review |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:417 Target#:42 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid